IQVIA Holdings Inc. $IQV Shares Bought by Principal Financial Group Inc.

Posted by on Jul 20th, 2026

Principal Financial Group Inc. lifted its holdings in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 3.6% during the first quarter, HoldingsChannel reports. The institutional investor owned 196,198 shares of the medical research company’s stock after purchasing an additional 6,897 shares during the period. Principal Financial Group Inc.’s holdings in IQVIA were worth $33,460,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the business. First Growth Capital LLC lifted its holdings in IQVIA by 3.2% in the first quarter. First Growth Capital LLC now owns 2,173 shares of the medical research company’s stock worth $375,000 after acquiring an additional 68 shares during the last quarter. Chicago Partners Investment Group LLC raised its position in shares of IQVIA by 1.5% during the 1st quarter. Chicago Partners Investment Group LLC now owns 4,635 shares of the medical research company’s stock worth $812,000 after purchasing an additional 70 shares during the period. Applied Finance Capital Management LLC lifted its holdings in shares of IQVIA by 11.4% in the 1st quarter. Applied Finance Capital Management LLC now owns 3,635 shares of the medical research company’s stock worth $620,000 after purchasing an additional 373 shares during the last quarter. Associated Banc Corp boosted its position in IQVIA by 2.7% during the 1st quarter. Associated Banc Corp now owns 181,003 shares of the medical research company’s stock valued at $30,868,000 after purchasing an additional 4,840 shares during the period. Finally, ARQ Wealth Advisors LLC acquired a new position in IQVIA during the 1st quarter valued at approximately $224,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of IQV stock opened at $206.26 on Monday. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $247.04. The stock has a fifty day moving average of $185.04 and a two-hundred day moving average of $187.88. The firm has a market capitalization of $34.42 billion, a PE ratio of 25.56, a price-to-earnings-growth ratio of 1.85 and a beta of 1.20.

IQVIA (NYSE:IQV – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The company had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same period last year, the company earned $2.70 earnings per share. The company’s quarterly revenue was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, research analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA announced that its Board of Directors has authorized a share repurchase program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on IQV. Weiss Ratings raised IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday. Robert W. Baird upped their price target on shares of IQVIA from $230.00 to $249.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 1st. Mizuho increased their price objective on shares of IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Wall Street Zen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday, June 27th. Finally, Morgan Stanley reissued an “equal weight” rating and set a $200.00 target price (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Fourteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and a consensus price target of $225.71.

Get Our Latest Stock Report on IQVIA

About IQVIA

(Free Report)

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Featured Stories

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.